Verinurad
Phase 2Small molecule
AstraZenecaVerinurad is one of 82 small molecule programs targeting Albuminuria. It is currently in Phase 2.
3
Indications
9
Total Trials
0
Active Trials
81
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
687 competitors in Heart Failure
#DrugCompanyPhaseTrials
1Brethine
SanofiPreclinical
Amidate
PfizerPreclinical
LCZ696
NovartisPreclinical
Verinurad
AstraZenecaPhase 2
Activase
RochePreclinical
Zemplar
AbbViePreclinical
Xifaxan
SSalix
Preclinical
Zoloft
VViatris Specialty LLC
Preclinical
Coumadin
AAbbott
Preclinical
Antidiabetic
FFederico II University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Tics2 trials
Dapagliflozin1 trial
ESS1 trial
Drug1 trial
3 more indications
Chronic Kidney Disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Verinurad. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company